VM-26 as a second drug in the treatment of brain gliomas

A. Kessinger; H. M. Lemon; J. F. Foley

VM-26 as a second drug in the treatment of brain gliomas

A. Kessinger, H. M. Lemon, J. F. Foley

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.

Original language	English (US)
Pages (from-to)	511-512
Number of pages	2
Journal	Cancer treatment reports
Volume	63
Issue number	3
State	Published - 1979
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{ecb1aa8abe04426f88f2599ee16e45aa,

title = "VM-26 as a second drug in the treatment of brain gliomas",

abstract = "Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.",

author = "A. Kessinger and Lemon, {H. M.} and Foley, {J. F.}",

year = "1979",

language = "English (US)",

volume = "63",

pages = "511--512",

journal = "Cancer treatment reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - VM-26 as a second drug in the treatment of brain gliomas

AU - Kessinger, A.

AU - Lemon, H. M.

AU - Foley, J. F.

PY - 1979

Y1 - 1979

N2 - Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.

AB - Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0018774584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018774584&partnerID=8YFLogxK

M3 - Article

C2 - 427830

AN - SCOPUS:0018774584

SN - 0361-5960

VL - 63

SP - 511

EP - 512

JO - Cancer treatment reports

JF - Cancer treatment reports

IS - 3

ER -

VM-26 as a second drug in the treatment of brain gliomas

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this